Kevin Outterson
Profiles

Kevin Outterson, JD, LLM

Professor of Health Law, Ethics & Human Rights, Health Law, Policy & Management - Boston University School of Public Health

(617) 358-2047
mko@bu.edu
Talbot
View Full Profile at BUMC

Biography

Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Other Positions

  • Professor of Law and N. Neal Pike Scholar, Health and Disability Law - Boston University School of Law
  • Executive Director of CARB-X, Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) - Boston University School of Law

Education

  • Northwestern University School of Law, JD Field of Study: Law
  • University of Cambridge, LLM Field of Study: Law
  • Northwestern University, BS Field of Study: History/Rhetoric

Websites

Publications

  • Published on 9/8/2025

    Goh M, McEnany M, Freeman R, Newton M, Kesselheim AS, Outterson K. Bridging the fair share gap for antibacterial innovation: an observational analysis of antibacterial revenues in the G7 and EU27. EClinicalMedicine. 2025 Oct; 88:103485. PMID: 40989242.

     Read At: PubMed
  • Published on 8/28/2025

    Weldon I, Liddell K, Outterson K. Policy Options for Antimicrobial Resistance: Exploring Lessons From Environmental Governance. Milbank Q. 2025 Aug 28. PMID: 40876865.

     Read At: PubMed
  • Published on 7/2/2025

    Goh M, Outterson K, Kesselheim AS. Examining Pricing and Availability for Neglected Tropical Disease Therapies in the United States. Open Forum Infect Dis. 2025 Jul; 12(7):ofaf391. PMID: 40689243.

     Read At: PubMed
  • Published on 4/30/2025

    Mossialos E, Outterson K, Davies S, Anderson M. The antimicrobial resistance cube: a framework for identifying policy gaps and driving action. Lancet. 2025 Apr 30. PMID: 40318688.

     Read At: PubMed
  • Published on 3/24/2025

    Robertson C, McCuskey E, Ahmed A, Lomax D, Zeiler K, McCarthy D, Stephens L, Ulrich M, Vernaglia L, Duryea DP, Huberfeld N, Outterson K. Celebrating 70 Years of Health Law at BU. Am J Law Med. 2024 Dec; 50(3-4):149-160. PMID: 40126117.

     Read At: PubMed
  • Published on 11/29/2024

    Chong CE, Pham TM, Carey ME, Wee BA, Taouk ML, Favieres JF, Moore CE, Dyson ZA, Lim C, Brown CL, Williamson D, Opatowski L, Outterson K, Mukiri KM, Sherry NL, Essack SY, Brisse S, Grad YH, Baker KS. Conference report of the 2024 Antimicrobial Resistance Meeting. NPJ Antimicrob Resist. 2024 Nov 29; 2(1):43. PMID: 39843763.

     Read At: PubMed
  • Published on 11/28/2024

    Goh M, Kesselheim AS, Outterson K. Azithromycin to Reduce Mortality. N Engl J Med. 2024 Nov 28; 391(21):2060. PMID: 39602642.

     Read At: PubMed
  • Published on 9/20/2024

    Balasegaram M, Outterson K, Røttingen JA. The time to address the antibiotic pipeline and access crisis is now. Lancet. 2024 Oct 12; 404(10461):1385-1387. PMID: 39312929.

     Read At: PubMed
  • Published on 6/14/2024

    Anderson M, Towse A, Outterson K, Mossialos E. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action. Lancet Microbe. 2024 Oct; 5(10):100886. PMID: 38885690.

     Read At: PubMed
  • Published on 5/23/2024

    Laxminarayan R, Impalli I, Rangarajan R, Cohn J, Ramjeet K, Trainor BW, Strathdee S, Sumpradit N, Berman D, Wertheim H, Outterson K, Srikantiah P, Theuretzbacher U. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance. Lancet. 2024 Jun 08; 403(10443):2534-2550. PMID: 38797178.

     Read At: PubMed

View 89 more publications:View Full Profile at BUMC

News & In the Media

View all profiles